PTC Therapeutics, Inc. (NASDAQ:PTCT) – Equities researchers at William Blair lowered their Q4 2019 EPS estimates for PTC Therapeutics in a research note issued to investors on Tuesday, November 6th. William Blair analyst R. Prasad now expects that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their previous estimate of $0.02. William Blair has a “Buy” rating on the stock.

A number of other equities research analysts have also issued reports on PTCT. Zacks Investment Research lowered shares of PTC Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday. Barclays reduced their target price on shares of PTC Therapeutics from $43.00 to $40.00 and set an “equal weight” rating on the stock in a report on Tuesday. ValuEngine lowered shares of PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Royal Bank of Canada reduced their target price on shares of PTC Therapeutics from $51.00 to $46.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Credit Suisse Group began coverage on shares of PTC Therapeutics in a report on Thursday, July 19th. They set an “outperform” rating and a $49.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $46.25.

PTC Therapeutics stock opened at $33.76 on Thursday. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -16.71 and a beta of 2.21. PTC Therapeutics has a 52-week low of $14.87 and a 52-week high of $52.95. The company has a current ratio of 2.73, a quick ratio of 4.18 and a debt-to-equity ratio of 0.37.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.66). The company had revenue of $53.59 million for the quarter, compared to analysts’ expectations of $70.56 million. PTC Therapeutics had a negative return on equity of 27.95% and a negative net margin of 30.61%. The business’s revenue for the quarter was up 28.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.82) EPS.

A number of institutional investors have recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co. NY lifted its holdings in PTC Therapeutics by 13.5% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 14,769 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 1,753 shares in the last quarter. MetLife Investment Advisors LLC raised its holdings in shares of PTC Therapeutics by 9.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 21,050 shares of the biopharmaceutical company’s stock valued at $710,000 after purchasing an additional 1,850 shares in the last quarter. Elk Creek Partners LLC raised its holdings in shares of PTC Therapeutics by 0.8% in the 3rd quarter. Elk Creek Partners LLC now owns 271,035 shares of the biopharmaceutical company’s stock valued at $12,739,000 after purchasing an additional 2,211 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of PTC Therapeutics by 4.2% in the 1st quarter. Wells Fargo & Company MN now owns 79,356 shares of the biopharmaceutical company’s stock valued at $2,148,000 after purchasing an additional 3,199 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of PTC Therapeutics by 15.1% in the 1st quarter. Principal Financial Group Inc. now owns 28,171 shares of the biopharmaceutical company’s stock valued at $762,000 after purchasing an additional 3,704 shares in the last quarter. Institutional investors own 85.72% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.

Featured Story: Cost of Capital Explained

Earnings History and Estimates for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.